Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n = 14), 320...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Tam, Constantine S., Opat, Stephen, Simpson, David, Cull, Gavin, Munoz, Javier, Phillips, Tycel J., Kim, Won Seog, Rule, Simon, Atwal, Siminder Kaur, Wei, Rachel, Novotny, William, Huang, Jane, Wang, Michael, Trotman, Judith
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270663/
https://ncbi.nlm.nih.gov/pubmed/34152395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020004074
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados